Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program

Flore Sicre De Fontbrune, Mony Fahd, Édouard Forcade, Suzanne Tavitian, Cécile Moluçon Chabrot, Fiorenza Barraco, Yosr Hicheri, Delphine Lebon, Sébastien Maury, Anne-Lise Menard, Barbara Możejko-Pastewka, Kevin D Wolter, Bruno Valtier, Thierry Leblanc, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 1347.

https://doi.org/10.1182/blood-2023-186493

Published: 2023

Journal Articles

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Blood (2023) 142 (Supplement 1): 571.

https://doi.org/10.1182/blood-2023-180780

Published: 2023

Journal Articles

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Jules Higué, Pierre-Yves Dumas, Laetitia Largeaud, Audrey Bidet, Émilie Klein, Olivier Mansier, Lucie Rigolot, Eric Delabesse, Anne Banos, Suzanne Tavitian, Thibaut Leguay, Sarah Guenounou, Edouard Forcade, Sarah Bertoli, Arnaud Pigneux, Christian Recher

Blood (2023) 142 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2023-180773

Published: 2023

Journal Articles

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Camille Gondran, Pierre-Yves Dumas, Audrey Bidet, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Françoise Huguet, Isabelle Luquet, Émilie Klein, Audrey Sarry, Anne-Charlotte De Grande, Eric Delabesse, Édouard Forcade, Cécile Borel, Arnaud Pigneux, Christian Recher, Laetitia Largeaud, Sarah Bertoli

Blood (2023) 142 (Supplement 1): 1473.

https://doi.org/10.1182/blood-2023-180817

Published: 2023

Journal Articles

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Blood (2023) 142 (Supplement 1): 7443.

https://doi.org/10.1182/blood-2023-182117

Published: 2023

Journal Articles

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Blood (2022) 140 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2022-171469

Published: 2022

Journal Articles

Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study

Pierre Luc Mouchel, Sarah Bertoli, Emilie Berard, Francois Vergez, Jean-Baptiste Rieu, Isabelle Luquet, Laetitia Largeaud, Nathan Guiraud, Jean-Emmanuel Sarry, Audrey Sarry, Francoise Huguet, Suzanne Tavitian, Christian Recher

Blood (2022) 140 (Supplement 1): 3239–3241.

https://doi.org/10.1182/blood-2022-166373

Published: 2022

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Blood (2021) 138 (Supplement 1): 872.

https://doi.org/10.1182/blood-2021-147735

Published: 2021

Journal Articles

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Laetitia Largeaud, Sarah Bertoli, Emilie Berard, Suzanne Tavitian, Muriel Picard, Stephanie Dufrechou, Naïs Prade, Francois Vergez, Jean-Baptiste Rieu, Isabelle Luquet, Audrey Sarry, Francoise Huguet, Jean Ruiz, Veronique De Mas, Eric Delabesse, Christian Recher

Blood (2021) 138 (Supplement 1): 1294.

https://doi.org/10.1182/blood-2021-147497

Published: 2021

Journal Articles

Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia

Ibrahim Didi, David Simoncini, Francois Vergez, Pierre-Yves Dumas, Suzanne Tavitian, Laetitia Largeaud, Audrey Bidet, Jean-Baptiste Rieu, Isabelle Luquet, Nicolas Lechevalier, Eric Delabesse, Audrey Sarry, Anne-Charlotte De Grande, Emilie Berard, Arnaud Pigneux, Christian Recher, Jean-Marc Alliot, Sarah Bertoli

Blood (2021) 138 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2021-145122

Published: 2021

Journal Articles

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Blood (2019) 134 (Supplement_1): 840.

https://doi.org/10.1182/blood-2019-130009

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Blood (2018) 132 (Supplement 1): 1444.

https://doi.org/10.1182/blood-2018-99-112825

Published: 2018

Journal Articles

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Emilie Berard, MD, Noemie Gadaud, Audrey Sarry, Francoise Huguet, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2018) 132 (Supplement 1): 2802.

https://doi.org/10.1182/blood-2018-99-113109

Published: 2018

Journal Articles

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Francoise Huguet, MD, Muriel Picard, MD, Francois Vergez, DVM, PhD, Eric Delabesse, MD PhD, Audrey Sarry, Emilie Berard, MD, Christian Recher, MD PhD

Blood (2017) 130 (Supplement 1): 3903.

https://doi.org/10.1182/blood.V130.Suppl_1.3903.3903

Published: 2017

Journal Articles

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Eric Delabesse, PharmD, PhD, Audrey Sarry, Françoise Huguet, MD, Christian Récher, MD PhD

Blood (2016) 128 (22): 1718.

https://doi.org/10.1182/blood.V128.22.1718.1718

Published: 2016

Journal Articles

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Christian Récher, MD PhD, Sarah Bertoli, MD PhD, Muriel Picard, MD, Emilie Bérard, MD PhD, Clément Larrue, PhD, Suzanne Tavitian, MD, Francois Vergez, DVM, PhD, Edwige Yon, Jean Ruiz, MD, Eric Delabesse, PharmD, PhD, Isabelle Luquet, MD, Laetitia Linares, PhD, Martin Carroll, MD, Audrey Sarry, Françoise Huguet, MD, Jean-Emmanuel Sarry, PhD

Blood (2016) 128 (22): 1636.

https://doi.org/10.1182/blood.V128.22.1636.1636

Published: 2016

Journal Articles

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Blood (2016) 128 (22): 3128.

https://doi.org/10.1182/blood.V128.22.3128.3128

Published: 2016

Journal Articles

Platelet Transfusion Refractoriness Following Induction Chemotherapy in Acute Myeloid Leukemia

Thibault Comont, Suzanne Tavitian, MD, Laurent Bardiaux, Marylise Fort, Benedicte Debiol, Daniele Morere, Françoise Huguet, MD, Christian Récher, MD PhD, Sarah Bertoli, MD PhD

Blood (2016) 128 (22): 3987.

https://doi.org/10.1182/blood.V128.22.3987.3987

Published: 2016

NARROW

Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry

Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1 : Time to Reconsider Prognostic Risk? a Study from the Dataml Registry

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia

Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry

Platelet Transfusion Refractoriness Following Induction Chemotherapy in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only